Subtopic Deep Dive
Etiology and Risk Factors of Cerebral Venous Thrombosis
Research Guide
What is Etiology and Risk Factors of Cerebral Venous Thrombosis?
Etiology and risk factors of cerebral venous thrombosis encompass hypercoagulable states, prothrombotic genetic mutations, dehydration, pregnancy, and acquired triggers like COVID-19 vaccination that predispose to CVST.
CVST arises from multifactorial risks including genetic prothrombin G20210A mutation (Reuner et al., 1998, 159 citations) and prothrombotic conditions in children (Wasay et al., 2007, 186 citations). Recent studies link Ad26.COV2.S vaccination (See et al., 2021, 538 citations) and COVID-19 infection (Cavalcanti et al., 2020, 260 citations) to CVST with thrombocytopenia. Over 10 key papers from 1998-2024 detail these associations, with epidemiological cohorts emphasizing young women and neonates.
Why It Matters
Identifying genetic risks like prothrombin G20210A mutation enables targeted screening and prevention in high-risk families (Reuner et al., 1998). Vaccine-related CVST cases post-Ad26.COV2.S informed clinical guidelines and resumed vaccination protocols (See et al., 2021). Pediatric cohort studies guide management in children, reducing morbidity through early risk factor recognition (Wasay et al., 2007). These insights support primary prevention in young women during pregnancy and prothrombotic states (Capecchi et al., 2018).
Key Research Challenges
Distinguishing Transient vs Genetic Risks
Differentiating reversible triggers like dehydration from inherited mutations like prothrombin G20210A complicates screening (Reuner et al., 1998). Multicenter cohorts show 35% neonates with unclear etiologies (Wasay et al., 2007). Guidelines stress comprehensive testing for unusual site thrombosis (Tait et al., 2012).
Quantifying Vaccine-Associated Risks
Post-vaccination CVST cases with thrombocytopenia require incidence calculations amid confounding factors (See et al., 2021, 538 citations). COVID-19 linkage adds complexity in hypercoagulable states (Cavalcanti et al., 2020). American Heart Association statements highlight vulnerable populations (Saposnik et al., 2024).
Multifactorial Risk Interactions
Interactions between pregnancy, obesity, and genetic factors evade simple models (Biousse et al., 2012). Reviews note overlooked presentations in comprehensive analyses (Idiculla et al., 2020). Red flags aid secondary headache identification but miss subtle risks (Phu et al., 2018).
Essential Papers
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021
Isaac See, John R. Su, Allison Lale et al. · 2021 · JAMA · 538 citations
The initial 12 US cases of CVST with thrombocytopenia after Ad26.COV2.S vaccination represent serious events. This case series may inform clinical guidance as Ad26.COV2.S vaccination resumes in the...
Red and orange flags for secondary headaches in clinical practice
Thien Phu, Angelique Remmers, Henrik Winther Schytz et al. · 2018 · Neurology · 350 citations
A minority of headache patients have a secondary headache disorder. The medical literature presents and promotes red flags to increase the likelihood of identifying a secondary etiology. In this re...
Update on the pathophysiology and management of idiopathic intracranial hypertension
Valérie Biousse, Bonnie Bruce, Nancy J. Newman · 2012 · Journal of Neurology Neurosurgery & Psychiatry · 270 citations
Idiopathic intracranial hypertension is a disease of unknown aetiology, typically affecting young obese women, producing a syndrome of increased intracranial pressure without identifiable cause. De...
Cerebral Venous Thrombosis Associated with COVID-19
Daniel D. Cavalcanti, Eytan Raz, Maksim Shapiro et al. · 2020 · American Journal of Neuroradiology · 260 citations
Despite the severity of coronavirus disease 2019 (COVID-19) being more frequently related to acute respiratory distress syndrome and acute cardiac and renal injuries, thromboembolic events have bee...
Cerebral venous sinus thrombosis
Marco Capecchi, Maria Abbattista, Ida Martinelli · 2018 · Journal of Thrombosis and Haemostasis · 203 citations
Cerebral Venous Thrombosis: A Comprehensive Review
Pretty Sara Idiculla, Dhineshreddy Gurala, M. Palanisamy et al. · 2020 · European Neurology · 190 citations
Background: Cerebral sinus venous thrombosis (CSVT) is a relatively rare, potentially fatal neurological condition that can be frequently overlooked due to the vague nature of its clinical and radi...
Cerebral Venous Sinus Thrombosis in Children: A Multicenter Cohort From the United States
Mohammad Wasay, Alper Dai, Mohsin Ansari et al. · 2007 · Journal of Child Neurology · 186 citations
This study presents a large multicenter cohort of children with cerebral venous thrombosis from 5 centers in the United States and analyzes their clinical findings and risk factors. Seventy patient...
Reading Guide
Foundational Papers
Start with Reuner et al. (1998) for prothrombin G20210A mutation evidence; Wasay et al. (2007) for pediatric risks; Tait et al. (2012) for unusual site guidelines—these establish genetic and cohort baselines.
Recent Advances
Study See et al. (2021) for vaccine associations; Saposnik et al. (2024) for AHA management updates; Cavalcanti et al. (2020) for COVID-19 links.
Core Methods
Cohort epidemiology (Wasay et al., 2007), genetic mutation analysis (Reuner et al., 1998), case series with thrombocytopenia scoring (See et al., 2021), and guideline-based risk stratification (Saposnik et al., 2024).
How PapersFlow Helps You Research Etiology and Risk Factors of Cerebral Venous Thrombosis
Discover & Search
Research Agent uses searchPapers and exaSearch to query 'prothrombin G20210A CVST risk,' retrieving Reuner et al. (1998) as top hit with 159 citations, then citationGraph maps 50+ forward citations linking to See et al. (2021) vaccine cases and findSimilarPapers uncovers pediatric cohorts like Wasay et al. (2007).
Analyze & Verify
Analysis Agent applies readPaperContent to extract risk factor tables from Saposnik et al. (2024), verifies prevalence claims via verifyResponse (CoVe) against OpenAlex data, and runs PythonAnalysis with pandas to compute odds ratios from cohort stats in Wasay et al. (2007), assigning GRADE B evidence for genetic risks.
Synthesize & Write
Synthesis Agent detects gaps in vaccine-genetic interactions via contradiction flagging across See et al. (2021) and Reuner et al. (1998), while Writing Agent uses latexEditText, latexSyncCitations, and latexCompile to generate a risk factor review manuscript with exportMermaid diagrams of prothrombotic pathways.
Use Cases
"Calculate odds ratio of prothrombin mutation in CVST from Reuner 1998 cohort"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas logistic regression on extracted genotype data) → odds ratio plot and p-value output.
"Draft LaTeX review on CVST vaccine risks citing See 2021 and Saposnik 2024"
Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (add 10 papers) → latexCompile → PDF with risk timeline figure.
"Find GitHub code for CVST genetic risk modeling from recent papers"
Research Agent → searchPapers 'CVST genetic analysis code' → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runnable Jupyter notebook for prothrombin mutation simulation.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ CVST etiology papers: searchPapers → citationGraph → GRADE grading → structured report on risk ORs. DeepScan applies 7-step analysis to See et al. (2021): readPaperContent → verifyResponse → runPythonAnalysis for incidence stats → checkpoint validation. Theorizer generates hypotheses on vaccine-hypercoagulable interactions from Reuner et al. (1998) and Cavalcanti et al. (2020).
Frequently Asked Questions
What defines etiology of CVST?
Etiology includes hypercoagulable states, genetic mutations like prothrombin G20210A, dehydration, pregnancy, and recent triggers like Ad26.COV2.S vaccination (See et al., 2021; Reuner et al., 1998).
What are main methods for risk factor studies?
Epidemiological cohorts (Wasay et al., 2007), genetic sequencing for mutations (Reuner et al., 1998), and case series post-vaccination or COVID-19 (See et al., 2021; Cavalcanti et al., 2020).
What are key papers on CVST risks?
See et al. (2021, 538 citations) on vaccine thrombocytopenia; Reuner et al. (1998, 159 citations) on prothrombin mutation; Wasay et al. (2007, 186 citations) on pediatric cohorts.
What open problems exist in CVST etiology?
Quantifying multifactorial interactions, low-incidence vaccine risks, and neonate-specific triggers remain unresolved (Saposnik et al., 2024; Idiculla et al., 2020).
Research Cerebral Venous Sinus Thrombosis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Etiology and Risk Factors of Cerebral Venous Thrombosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cerebral Venous Sinus Thrombosis Research Guide